Last year subcutaneous sumatriptan (Imigran – Glaxo) was introduced in Britain as “a revolutionary acute therapy in migraine”. The claims were repeated when an oral preparation was launched earlier this year. Sumatriptan is licensed for the acute relief of migraine attacks with or without aura; the subcutaneous preparation is also licensed for the treatment of cluster headache.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.